Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 Presenter Profiles

Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 takes place May 15-16 in Monte Carlo.

For in-depth information about the event visit http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf9.

Below are profiles from Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 presenters; breaking news releases are available at http://www.tradeshownews.com, Business Wire's event news resource.

Business Wire is the official news wire service for Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006. -0- Company: Active Biotech AB Ticker Symbol & Exchange: ACTI.SE SEK Investor Relations Contact: Cecilia Hofvander Investor Relations Contact Phone: [phone] Web: www.activebiotech.com Date of Presentation: May 16 Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex(R) for RA Company: Advancis Pharmaceutical Corp. Ticker Symbol & Exchange: AVNC: NASDAQ Investor Relations Contact: Bob Bannon Investor Relations Contact Phone: [phone] Web: www.advancispharm.com Date of Presentation: 05/16/2006 Advancis is a pharmaceutical company focused on developing and commercializing anti-infective drug products that fulfill unmet medical needs in the treatment of infectious disease. Based on the Company's finding that bacteria exposed to antibiotics in sequential bursts, or pulses, are killed more efficiently than those exposed to standard treatment regimens, Advancis has developed a proprietary, once-a-day pulsatile delivery technology for antibiotics and other anti-infectives called PULSYS(TM). The Company has an ongoing Phase III clinical trial for an Amoxicillin PULSYS product, is currently selling the Keflex brand of cephalexin, and is exploring a once-daily pulsatile formulation of Keflex. Company: AEterna Zentaris Inc. Ticker Symbol & Exchange: NASDAQ:AEZS TSX:AEZ Investor Relations Contact: Ms. Jenene Thomas Investor Relations Contact Phone: [phone] Web: www.aeternazentaris.com Date of Presentation: May 15, 2006 AEterna Zentaris Inc. (TSX:AEZ, NASDAQ:AEZS) is a growing global biopharmaceutical company focused on oncology and endocrine therapy with proven expertise in drug discovery, development and commercialization. AEterna Zentaris also owns 48.40% of the equity of Atrium Biotechnologies Inc. (TSX:ATB.sv) and 64.9% of its voting rights. Atrium is a developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutritional industries. Company: Altea Therapeutics Corporation Investor Relations Contact: Steven P. Damon Investor Relations Contact Phone: [phone] Web: http://www.alteatherapeutics.com Altea Therapeutics is a privately-held pharmaceutical company developing advanced transdermal patches that painlessly and efficiently deliver sustained therapeutic levels of proteins and water-soluble drugs. The Company is conducting human clinical trials in the US on two major product innovations: (i) hydromorphone and fentanyl patches for the rapid management of moderate to severe pain; and (ii) patches for providing basal levels of insulin for 12- or 24-hours thus addressing the needs of type 1 or type 2 diabetics. Furthermore, it is also conducting feasibility studies on using the PassPort(TM) System for the delivery of apomorphine (Parkinson's disease) and vaccines (disease prevention). Company: Alteon Inc. Ticker Symbol & Exchange: AMEX: ALT Investor Relations Contact: Susan Pietropaolo Investor Relations Contact Phone: [phone] Web: www.alteon.com Date of Presentation: May 15, 2006 Alteon recently announced a definitive merger agreement with privately-held HaptoGuard, Inc., and the granting of certain royalty and negotiation rights to Genentech, Inc. as part of the restructuring of Genentech's preferred stock position in Alteon. Alteon and HaptoGuard have complementary products under development in cardiovascular diseases and diabetes, including two Phase 2 clinical-stage compounds. Data is expected around year-end 2006 from two Phase 2 trials of HaptoGuard's BXT-51072 for reduction of mortality in post-myocardial infarction patients with diabetes. Alteon's alagebrium, which has been shown to improve cardiac function including the ability to significantly reduce left ventricular mass, is being developed for heart failure. Company: Amarin Corporation Ticker Symbol & Exchange: NASDAQ (AMRN) Investor Relations Contact: Rick Stewart, CEO Investor Relations Contact Phone: [phone] Web: www.amarincorp.com Date of Presentation: May 15, 2006 Amarin is a neuroscience company focused on the research, development and commercialization of novel drugs for the treatment of central nervous system disorders. Miraxion, Amarin's lead development compound, is in Phase III development for Huntington's disease, Phase II development for depressive disorders and preclinical development for Parkinson's disease. Miraxion for Huntington's disease is being developed under a Special Protocol Assessment agreed with the US Food and Drug Administration ("FDA"), has been granted fast track designation by the FDA and has received orphan drug designation in the US and Europe. Company: Ambrilia Biopharma Inc. Ticker Symbol & Exchange: TSX:AMB Investor Relations Contact: Julie M. Thibodeau Investor Relations Contact Phone: [phone] ext. 235 Web: www.ambrilia.com Date of Presentation: May 16, 2006 - 3:40-4:00 pm Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases. Ambrilia's product portfolio includes mid to early-stage products (PPL-100, PCK3145, TVT-Dox, SPC3) and two specialty generics (Octreotide and Goserelin), the first of which is late-stage and value-added. With these products, Ambrilia Biopharma expects to accelerate its path to profitability by generating potential revenues through U.S. and European sales of Octreotide and European sales of Goserelin. Ambrilia's head office, Research and Development and Manufacturing facilities are located in Montreal with a regional office in France. Ambrilia's common shares are traded on the Toronto Stock Exchange under the ticker symbol AMB Company: Antares Pharma, Inc. Ticker Symbol & Exchange: Amex: AIS Investor Relations Contact: Stephanie M. Baldwin Investor Relations Contact Phone: [phone] Web: www.antarespharma.com Date of Presentation: May 15, 2006 Antares Pharma is a specialized pharma product development company focused on developing patented drug delivery platforms including its recently announced TecTix(TM)system for topical and transmucosal delivery, ATD(TM) Advanced Transdermal Delivery system, Easy Tec(TM) fast-melt oral tablets, disposable mini-needle injection systems (Vibex(TM)), and reusable needle-free injection systems (VISION(R) and Valeo(TM)). Company: Arbios Systems, Inc. Ticker Symbol & Exchange: OTCBB: ABOS Investor Relations Contact: Paula Schwartz Investor Relations Contact Phone: Rx Communications Group, 917-322-2216 Web: http://www.arbios.com Date of Presentation: May 15, 2006, 11:05am Eastern Time Arbios Systems, Inc. is developing proprietary medical devices and cell-based therapies to enhance the survival of the millions of patients who experience, or are at risk of, life threatening episodes of liver failure. Arbios' pipeline includes the SEPET(TM) Liver Assist Device, currently demonstrating favorable outcomes in a U.S. clinical feasibility trial in patients experiencing acute exacerbation of chronic liver disease, and the HepatAssist(TM) Cell-Based Liver Support System, combining blood detoxification with liver cell therapy to provide replacement of whole liver function. HepatAssist(TM) has been shown in a Phase II-III clinical trial to enhance survival of acute liver failure patients. Company: AVANT Immunotherapeutics, Inc. Ticker Symbol & Exchange: NASDAQ: AVAN Investor Relations Contact: Paula Freeman Investor Relations Contact Phone: [phone] Web: www.avantimmune.com Date of Presentation: May 15, 2005 AVANT Immunotherapeutics, Inc. discovers and develops innovative vaccines and therapeutics that harness the human immune system to prevent and treat disease. AVANT has three products on the market and six in clinical development. These include TP10 to reduce tissue damage associated with cardiac bypass surgery and a novel vaccine for cholesterol management. AVANT is developing a broad pipeline of vaccines for biodefense, travelers, global health, and pandemic flu needs based on its rapid-protecting, single-dose, temperature-stable vaccine technology for oral delivery. AVANT has received $50M over the last 12 months in financings from Paul Royalty Fund for future Rotarix(R) royalty revenues. Company: Bentley Pharmaceuticals, Inc. Ticker Symbol & Exchange: NYSE: BNT Investor Relations Contact: Tara Spiess Investor Relations Contact Phone: [phone] Web: www.bentleypharm.com Date of Presentation: May 15, 2006 Bentley Pharmaceuticals, Inc. is a vertically integrated specialty pharmaceutical company with a growing, profitable international generic business and two proprietary drug-delivery platform technologies, which have broad potential to replace injections and improve health outcomes. Bentley's revenues and profits come primarily from the company's growing portfolio of generic pharmaceuticals, currently marketed in the EU. Over the past five years, Bentley's most advanced drug-delivery technology, CPE-215, has already led to the development of a marketed product, TESTIM, a topical testosterone gel licensed to Auxilium Pharmaceuticals. Clinical trials are under way for the development of intranasal administration of insulin. Company: BioBalance Corp. Ticker Symbol & Exchange: BBAL: OTCBB Investor Relations Contact: Simon Fischer Investor Relations Contact Phone: [phone] Web: www.biobalance.com Date of Presentation: May 16, 2006 BioBalance is a biopharmaceutical company focused on the development of novel treatments for gastrointestinal disorders that are poorly addressed by current therapies. These include pouchitis, Irritable Bowel Syndrome, Crohn's disease, ulcerative colitis, C. difficile infections and celiac disease. The company's lead product, PROBACTRIX (R), is a proprietary strain of non-pathogenic E.coli M17 bacteria that restores the microbial balance to the digestive system. Prior overseas studies have confirmed that this product works across a wide range of GI disorders and should be viewed as a platform technology. On March 24, 2006, BioBalance received FDA approval to begin phase II clinical trials. Company: BioMarin Pharmaceutical Inc. Ticker Symbol & Exchange: Nasdaq/SWX: BMRN Investor Relations Contact: Joshua Grass Investor Relations Contact Phone: [phone] Web: www.BMRN.com Date of Presentation: Monday, May 15, 2006 BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple investigational product candidates. Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Additionally, BioMarin has rights to receive payments and royalties related to Orapred(R) (prednisolone sodium phosphate oral solution). Investigational product candidates include Phenoptin(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU). Company: Bioniche Life Sciences Inc. Ticker Symbol & Exchange: TSX: BNC Investor Relations Contact: Jennifer Shea Investor Relations Contact Phone: [phone] Web: www.Bioniche.com Date of Presentation: Tuesday, May 16, 2006 Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 185 skilled personnel and has three principal operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in these three segments. The first of these therapies is for the treatment of bladder cancer. Recruitment for two FDA-approved Phase III clinical trials will begin later in 2006. Company: BioSante Pharmaceuticals, Inc. Ticker Symbol & Exchange: BPA--Amex Investor Relations Contact: Phillip Donenberg Investor Relations Contact Phone: [phone] ext 101 Web: www.biosantepharma.com Date of Presentation: April 11, 2006 BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Bio-E-Gel(TM) (transdermal estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel(TM) (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD). A Bio-E-Gel new drug application (NDA) was submitted to the FDA on February 16, 2006. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Company: BioSphere Medical, Inc. Ticker Symbol & Exchange: BSMD Investor Relations Contact: Maura Gedid Investor Relations Contact Phone: [phone] Web: www.biospheremed.com Date of Presentation: May 15, 2006 BioSphere Medical applies its proprietary, bioengineered microsphere technology to a variety of medical therapies through the use of embolotherapy. Embolotherapy works by reducing blood flow to targeted areas of the body. The Company is the world leader in the growing Uterine Fibroid Embolization market, and is also active in the treatment of liver cancer using embolization. Company: Boston Life Sciences, Inc. Ticker Symbol & Exchange: NASDAQ: BLSI Investor Relations Contact: Sharon Correia Investor Relations Contact Phone: [phone] Web: www.bostonlifesciences.com Date of Presentation: 5/15/2006 from 3:20pm - 3:40pm Boston Life Sciences is a biopharmaceutical company engaged in the research and development of diagnostic and therapeutic products for CNS disorders. Its Molecular Imaging Program includes ALTROPANE(R) molecular imaging agent, currently in Phase III development for diagnosing Parkinson's disease, and in Phase II development for diagnosing ADHD. BLSI also has a preclinical development program focused on next generation imaging agents for diagnosing CNS disorders using SPECT, PET and MRI imaging. In the Company's Axon Regeneration Program, INOSINE is aimed at functional recovery in stroke. BLSI's DAT blocker program is aimed at symptom management and modification of disease progression in PD and is in preclinical development. Company: Cellerant Therapeutics, Inc. Investor Relations Contact: Bruce Cohen, President & CEO Investor Relations Contact Phone: [phone] Web: http://www.cellerant.com Date of Presentation: 5/16/05 Cellerant Therapeutics, Inc. is a clinical-stage biotechnology company developing curative treatments for cancer and hematologic disorders using products derived from its knowledge of the human hematopoietic (blood forming) system and its ability to produce highly purified hematopoietic cell populations. The Company's commercial strategy is to develop (1) A cell purification platform (CLT-001) that will enable highly purified stem cell transplant-based therapy for the treatment of genetic blood disorders and cancer; (2) An off-the-shelf cell-based product (CLT-008) with multiple indications in the treatment of neutropenic patients; and (3) Antibody therapeutics targeting hematologic cancer stem cells. Company: Ceragenix Ticker Symbol & Exchange: CGXP Investor Relations Contact: Robert Stanislaro Investor Relations Contact Phone: [phone] Web: www.ceragenix.com Date of Presentation: May 15 at 5:15 EDT Ceragenix Pharmaceuticals, Inc. (OTCBB: CGXP - News) is a biopharmaceutical company that discovers, develops and commercializes novel anti-infective drugs based on its proprietary class of compounds, Ceragenins(TM) (or CSAs). Active against a broad range of gram positive and negative bacteria, these agents are being developed as anti-infective medical device coatings (Ceracides(TM)) and as therapeutics for antibiotic-resistant organisms. Ceragenix further owns exclusive rights to Barrier Repair Technology for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenix's patented Barrier Repair Technology, invented by Dr. Peter Elias and licensed from the University of California, is the platform for the development of two prescription topical creams--EpiCeram(R) and NeoCeram(R). Company: ChemGenex Pharmaceuticals Limited Ticker Symbol & Exchange: NASDAQ: CXSP Web: www.chemgenex.com Date of Presentation: May 15, 2006 ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes, obesity, and depression. ChemGenex's lead compound, Ceflatonin(R) (homoharringtonine or HHT), is currently in phase 2 clinical trials for a range of leukemias and Quinamed(R) (amonafide dihydrochloride), is in phase 2 clinical trials for prostate, breast and ovarian cancers. The company has a significant portfolio of cancer, diabetes, obesity and depression programs, several of which have been partnered with international pharmaceutical companies. Company: Ciphergen Biosystems, Inc. Ticker Symbol & Exchange: CIPH Nasdaq Investor Relations Contact: Sue Carruthers Investor Relations Contact Phone: [phone] Web: www.ciphergen.com Date of Presentation: Monday May 15, 3:40 p.m. Ciphergen is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research and process proteomics applications. ProteinChip Systems enable protein discovery, validation, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Company: CombinatoRx, Inc. Ticker Symbol & Exchange: CRXX Investor Relations Contact: Robert Forrester / Gina Nugent Investor Relations Contact Phone: [phone] Web: www.combinatorx.com Date of Presentation: Tuesday, May 16th CombinatoRx, Inc. is a biopharmaceutical company focused on developing new medicines built from synergistic combinations of approved drugs. In less than six years, we have discovered and advanced into clinical trials a portfolio of six product candidates targeting multiple immuno-inflammatory diseases and cancer, at a total investment, including development of our proprietary screening technology, of less than $50 million. We are developing our combination drugs in response to the understanding that many diseases affect the body through multiple biological pathways. Traditional drug discovery has focused on agents that target a single biological pathway. We believe that by targeting multiple pathways, our combination drug candidates may create synergistic therapeutic effects, which could result in improved treatments for many diseases. Company: CYCLACEL PHARMACEUTICALS, INC. Ticker Symbol & Exchange: CYCC (NASDAQ) Investor Relations Contact: Tara Spiess / Andrea Romstad Investor Relations Contact Phone: [phone] Web: www.cyclacel.com Date of Presentation: May 15, 2006 Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization for oncology indications of novel, mechanism-targeted drugs that affect the cancer cell cycle. Cyclacel's seliciclib, the leading orally-available Cyclin Dependent Kinase inhibitor, is in Phase II clinical trials for the treatment of non-small cell lung cancer. Sapacitabine, an orally-available, cell cycle modulating nucleoside analog, is in Phase I clinical trials for the treatment of cancer. CYC116, an orally available, Aurora kinase inhibitor, is in IND-directed preclinical development. Several additional programs are at an earlier stage. Cyclacel operates from facilities located in New Jersey, England and Scotland. Company: CYTOGEN Corporation Ticker Symbol & Exchange: CYTO Investor Relations Contact: Christopher P. Schnittker Investor Relations Contact Phone: [phone] Web: www.cytogen.com Date of Presentation: Monday, May 15, 2006 Founded in 1980, Cytogen Corporation of Princeton, NJ is a biopharmaceutical company dedicated to improving the lives of patients with cancer by acquiring, developing and commercializing innovative molecules targeting the sites and stages of cancer progression. Cytogen's marketed products include QUADRAMET(R) (samarium Sm-153 lexidronam injection), PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide and SOLTAMOX(TM) (tamoxifen citrate) in the United States. Cytogen's development pipeline includes CYT-500, a therapeutic radiolabeled antibody targeting PSMA. Company: Cytori Therapeutics Ticker Symbol & Exchange: NASDAQ: CYTX Investor Relations Contact: Tom Baker Investor Relations Contact Phone: [phone] Web: www.cytoritx.com Date of Presentation: May 15, 2006 Cytori Therapeutics, Inc., is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution(TM) System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. Company: CytRx Corporation Ticker Symbol & Exchange: CYTR (Nasdaq) Investor Relations Contact: Ed Umali Investor Relations Contact Phone: [phone] x309 Web: www.cytrx.com Date of Presentation: May 15, 2006 CytRx is a world leader in the development of high-value therapeutics utilizing its core technologies in small molecule drugs, RNAi drug discovery and DNA vaccines. The company's small molecule therapeutics program involves "molecular chaperone" oral drug candidates, the first of which is arimoclomol for the treatment of ALS (Lou Gehrig's disease), which is currently in a Phase II trial. CytRx announced favorable interim results from a DNA-based HIV vaccine Phase I clinical trial, and is conducting RNAi-based drug discovery research to identify new approaches to treat metabolic diseases. Additional programs currently underway address obesity, type 2 diabetes, cardiovascular disease and diabetic wound healing. Company: Dyadic International, Inc. Ticker Symbol & Exchange: AMEX:DIL Investor Relations Contact: Neil Berkman, Berkman Associates Investor Relations Contact Phone: [phone] Web: www.dyadic-group.com Date of Presentation: May 15, 2006 Dyadic develops, manufactures and sells biological products using proprietary fungal strains to produce enzymes and other biomaterials, principally focused on a system for protein production based on the patented C1 fungus. Dyadic sells enzyme products to global customers in the textile, pulp & paper, and animal feed industries, and is developing its C1 technology to facilitate the discovery, development and large-scale production of human antibodies and other high-value therapeutic proteins. Dyadic also is applying its technologies to develop and manufacture enzymes for the conversion of agricultural byproducts like corn stover and sugar cane bagasse into fermentable sugars that can be used to produce ethanol. Company: EntreMed, Inc. Ticker Symbol & Exchange: ENMD Investor Relations Contact: Ginny Dunn Investor Relations Contact Phone: [phone] Web: www.entremed.com Date of Presentation: Monday, May 15, 2006 EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing next generation multi-mechanism oncology and antiinflammatory drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. Panzem(R) (2-methoxyestradiol or 2ME2), one of the Company's lead drug candidates, is currently in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, a novel cell cycle inhibitor acquired through the recent acquisition of Miikana Therapeutics, is also in Phase 2 clinical trials for cancer. ENMD-1198, a novel tubulin binding agent discovered by EntreMed, is currently in Phase 1 clinical studies in patients with advanced cancer. Company: Evotec AG Ticker Symbol & Exchange: EVT at FSE Investor Relations Contact: Anne Hennecke Investor Relations Contact Phone: [phone] Web: www.evotec.com Date of Presentation: 15 May 2006, 12.40 pm Evotec is an international leader in the discovery and development of new, small-molecule drugs. In proprietary projects, Evotec specialises in finding new treatments for diseases of the central nervous system. Evotec has three Phase I clinical programmes: EVT 201 (GABA-A modulator) for the treatment of insomnia and EVT 101 (subtype selective NMDA receptor antagonist) & EVT 301 (selective and reversible inhibitor of MAO-B), both for the treatment of Alzheimer's disease. In contract research, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative and often integrated solutions from drug target to clinic through an unmatched range of capabilities, including early stage assay development/screening through to medicinal chemistry and drug manufacturing. Company: Faust Pharmaceuticals Investor Relations Contact: Thomas C. Seoh Investor Relations Contact Phone: Tel : [phone] Web: www.faustpharma.com Date of Presentation: May 15 Faust Pharmaceuticals is a clinical-stage product company specializing in discovering and developing drugs for nervous system diseases and conditions. The company's lead compound, FP0011, is a small molecule glutamate inhibitor in Phase II for ALS and Parkinson's disease. Another compound, FP0023, is a fetal gene activating utrophin inducer in preparation for Phase I/II for Duchenne Muscular Dystrophy. The company additionally has pre-clinical programs on targets such as mGluR (metabotropic glutamate receptor), as well as a proprietary drug discovery platform targeting GPCRs (G-Protein Coupled Receptors). Company: Favrille, Inc. Ticker Symbol & Exchange: Nasdaq: FVRL Investor Relations Contact: Pete De Spain Investor Relations Contact Phone: [phone] Web: www.favrille.com Date of Presentation: May 15, 2006 Favrille, Inc. is a biopharmaceutical company focused on the research, development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of T-cell lymphoma. Company: GammaCan International Inc Ticker Symbol & Exchange: OTCBB: GCAN Investor Relations Contact: Yaron Cherny Investor Relations Contact Phone: [phone] Web: www.GammaCan.com Date of Presentation: May 16th 08.40am GammaCan (OTCBB: GCAN.OB), is an Israeli biopharmaceutical company developing immunotherapies to treat cancer. GammaCan's treatment platform uses intravenous immunoglobulin (IVIg). The Company is in the process of applying for a US IND for VitiGam, GammaCan's second generation IVIg product. GammaCan intends to conduct a PhaseI/II trial to evaluate VitiGam in patients with stage 3 and 4 melanoma. VitiGam is based on IVIg manufactured from plasma of donors with vitiligo, a benign autoimmune skin condition. GammaCan scientists have demonstrated that vitiligo derived IVIg displays potent anti-melanoma activity model systems. GammaCan owns two issued U.S. patents and has several patent applications pending. Company: GENTA, INC. Ticker Symbol & Exchange: GNTA (NASDAQ) Investor Relations Contact: Tara Spiess/Andrea Romstad Investor Relations Contact Phone: [phone] Web: www.genta.com Date of Presentation: May 15, 2006 Genta is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. A New Drug Application (NDA) has been submitted to the U.S. Federal Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. The lead compound from Genta's Small molecule program is Ganite(R) (gallium nitrate injection), is approved for marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Company: GenVec, Inc. Ticker Symbol & Exchange: GNVC Investor Relations Contact: Tricia J. Richardson Investor Relations Contact Phone: [phone] Web: www.genvec.com Date of Presentation: Monday, May 15, 9:25 am GenVec, Inc. (Nasdaq: GNVC) is a biotechnology company developing innovative therapeutics to treat cancer, sensory deterioration (loss of vision and hearing) and heart disease. Our lead investigational drug is TNFerade(TM) for cancer, now in Phase II/III testing in pancreatic cancer and Phase II trials in rectal cancer and metastatic melanoma. Our core adenovector technology is also being used to develop vaccines for infectious diseases, including HIV and malaria, and for anti-viral protection against foot and mouth disease. We have three product development programs in various stages of clinical testing. Company: GPC Biotech AG Ticker Symbol & Exchange: FSE:GPC / NASDAQ:GPCB Investor Relations Contact: Martin Brandle Investor Relations Contact Phone: [phone] Web: www.gpc-biotech.com Date of Presentation: May 15, 2006 GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. The Company's lead product candidate - satraplatin - has achieved target enrollment in a Ph 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has begun the rolling NDA submission process for this compound. GPC Biotech is also developing a monoclonal antibody with a novel mechanism, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. Company: Hana Biosciences, Inc. Ticker Symbol & Exchange: NASDAQ: HNAB Investor Relations Contact: John Iparraguirre Investor Relations Contact Phone: [phone] Web: http://www.hanabiosciences.com Date of Presentation: Monday, May 15, 2006 Hana Biosciences (NASDAQ: HNAB) acquires, develops, and commercializes innovative products to advance cancer care. By collaborating with academia and research institutions, Hana identifies development stage product candidates that address unmet oncological needs. Using an experienced biopharmaceutical management team, Hana moves these unique product candidates through translational research for timely transfer from the lab to the clinical development. Multiple technologies with well-validated mechanisms of action and strong intellectual property rights set the platform for accelerated growth and speeds commercialization. Hana Bisociences is pleased to present at the Rodman and Reshaw Conference on May 15, 2006 at 8:40AM in the Atlantique Salon-Eastern. A webcast can be accessed on the investor relations page at www.hanabiosciences.com. Company: GTC Biotherapeutics Ticker Symbol & Exchange: GTCB NASDAQ Investor Relations Contact: Tom Newberry Investor Relations Contact Phone: [phone] Web: www.gtc-bio.com Date of Presentation: May 15, 2006 GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. In addition to GTC's lead product ATryn(R), the company is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine. GTC also enters into partnering arrangements, or external programs, in which its technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. Company: Hollis-Eden Pharmaceuticals, Inc. Ticker Symbol & Exchange: NASDAQ: HEPH Investor Relations Contact: Scott Rieger Investor Relations Contact Phone: [phone] Web: www.holliseden.com Date of Presentation: May 16 Hollis-Eden Pharmaceuticals is developing a proprietary new class of small molecule compounds that are metabolic conversion products or synthetic analogs of adrenal steroid hormones. These compounds have been demonstrated in humans to possess several properties with potential therapeutic benefit - they regulate innate and adaptive immunity, reduce nonproductive inflammation and stimulate cell proliferation. The Company's lead product candidate, NEUMUNE, is entering late-stage development for the treatment of Acute Radiation Syndrome, a life-threatening condition resulting from exposure to radiation following a nuclear or radiological incident. Hollis-Eden also is profiling second-generation compounds for potential clinical development in a broad spectrum of therapeutic categories. Company: Jerini AG Ticker Symbol & Exchange: JI4 Investor Relations Contact: Stacy Wiedenmann [e-mail] Investor Relations Contact Phone: [phone] Web: www.jerini.com Date of Presentation: May 16th, 2006 Jerini is a pharmaceutical company based in Berlin, Germany, focusing on the discovery and development of novel peptide-based drugs. The company selectively pursues disease indications for which patients have limited or no treatment options. Jerini's lead drug candidate, Icatibant, is currently in Phase III clinical trials in Europe, the United States, and other countries for the subcutaneous treatment of hereditary angioedema (HAE). The next most advanced compound is JSM 6427 for the treatment of age-related macular degeneration (AMD). Jerini's proprietary P2D discovery platform has been the basis for the development of these drugs. Company: Immtech Pharmaceuticals, Inc Ticker Symbol & Exchange: AMEX: IMM Investor Relations Contact: F. C. Thompson Investor Relations Contact Phone: [phone] Web: http://www.immtechpharma.com Date of Presentation: May 16, 2006 Immtech Pharmaceuticals is focused on advancing the development and commercialization of oral drugs to treat infectious diseases and other disorders with significant unmet needs. Immtech is in late-stage clinical trials with its first compound, pafuramidine maleate (DB289), for malaria, Pneumocystis pneumonia (PcP), and African sleeping sickness (trypanosomiasis). Immtech is also in drug development programs with other compounds for treating fungal infections and tuberculosis. Immtech holds exclusive worldwide licenses to patents, patent applications, and technology for products derived from a proprietary pharmaceutical platform. Company: Insmed Inc. Ticker Symbol & Exchange: NASDAQ: INSM Investor Relations Contact: Tim Ryan Investor Relations Contact Phone: [phone] Web: www.insmed.com Date of Presentation: Monday, May 15 Insmed is a biopharmaceutical company focused on the development and commercialization of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com. The company's leading product, IPLEX was approved as an orphan drug by the United States Food and Drug Administration in December 2005 for the treatment of growth failure in children with severe primary IGF-I deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Company: INYX, INC. Ticker Symbol & Exchange: IYXI: OTCBB Investor Relations Contact: Jay M. Green, Executive VP Investor Relations Contact Phone: [phone] Web: www.inyxgroup.com Date of Presentation: May 16, 2006 Inyx, Inc. is a specialty pharmaceutical company with niche drug delivery technologies and products. Inyx provides its development and production expertise to other pharmaceutcial companies on both a consulting and collaboration basis. In addition, Inyx is developing its own proprietary products. On April 3, 2006, Inyx announced that it reached an agreement in principle to acquire a German pharmaceutical production business from a pan-European specialty pharmaceutical company, with which it is also entering into a strategic, 10-year-plus collaboration agreement, whereby Inyx will become the exclusive manufacturing resource for the European company's therapeutic products. The acquisition, which is subject to completion of customary due diligence and execution of definitive documents , is expected to be completed by June 30, 2006. Company: Javelin Pharmaceuticals, Inc. Ticker Symbol & Exchange: OTC: JVPH.OB Investor Relations Contact: Donna LaVoie / June Gregg Investor Relations Contact Phone: [phone] Web: www.javelinpharmaceuticals.com Date of Presentation: Monday, May 15, 2006 Javelin's product candidates address the acute moderate-to-severe pain medication market segment. We are developing differentiated pain control products that provide the flexibility and versatility required to address the limitations of existing prescription pain medications. Our product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments. Javelin has three late stage product candidates in development: Dyloject(TM) (diclofenac sodium, injectable), Rylomine(TM) (intranasal morphine) and PMI-150 (intranasal ketamine). Company: Lorus Therapeutics Inc Ticker Symbol & Exchange: AMEX:LRP & TSX:LOR Investor Relations Contact: Grace Tse Investor Relations Contact Phone: [phone] x 380 Web: www.lorusthera.com Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. The Company develops new drugs that can be used, either alone or in combination, to successfully manage cancer. Through its own discovery efforts and an in-licensing and acquisition program, the Company is building a portfolio of anticancer drugs with low toxicities. Lorus has just completed a Phase III clinical trial, has eight Phase II clinical trials in seven cancer indications underway, and a strong preclinical drug program that is scheduled to bring a novel small molecule technology into clinical trial. Company: Manhattan Pharmaceuticals, Inc. Ticker Symbol & Exchange: AMEX: MHA Investor Relations Contact: Michelle Carroll Investor Relations Contact Phone: [phone] Web: www.manhattanpharma.com Date of Presentation: Tuesday, 16 May 2006 Manhattan Pharmaceuticals, Inc. (AMEX: MHA), a development stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures. Company: MEDICURE INC. Ticker Symbol & Exchange: AMEX: MCU & TSX: MPH Investor Relations Contact: HOGAN MULLALLY Investor Relations Contact Phone: [phone] Web: www.medicure.com Date of Presentation: MAY 15, 2006 Medicure is a cardiovascular focused drug development company. The Company's lead drug is a novel cardioprotectant called MC-1. MC-1 is set to commence pivotal Phase III testing for ischemic reperfusion injury, a common adverse event following restoration of blood flow post cardiac interventions such as CABG surgery and balloon angioplasty. There are currently no approved therapies to protect the heart from ischemic reperfusion injury, and MC-1 is the most advanced compound targeting the area. MC-1 has received FDA Fast Track Designation. Company: Medivation, Inc. Ticker Symbol & Exchange: MDV (AMEX) Investor Relations Contact: Patrick Machado Investor Relations Contact Phone: [phone] x201 Web: www.medivation.com Date of Presentation: May 15, 2006 Medivation, Inc. acquires promising pharmaceutical and medical device technologies in the late preclinical development phase, develops those technologies quickly and cost-effectively through human first proof-of-efficacy studies (generally the end of Phase 2 clinical trials), and seeks to sell or partner successful programs with larger pharmaceutical, biotechnology and medical device companies for late-stage clinical studies and commercialization. Medivation's current portfolio consists of small molecule drugs in development to treat 3 large, unmet medical needs - Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer, the last two of which are likely Orphan Drug indications. Company: MIGENIX Inc. Ticker Symbol & Exchange: TSX: MGI; OTC: MGIFF Investor Relations Contact: Arthur Ayres, CFO Investor Relations Contact Phone: [phone] ext.233 Web: www.migenix.com Date of Presentation: Tuesday, May 16th (9:45am) MIGENIX Inc. is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the prevention of catheter-related infections (Phase III), the treatment of chronic hepatitis C virus (HCV) infections (Phase II), and the treatment of neurodegenerative diseases (Phase I) and the treatment of acne (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Company: MorphoSys AG Ticker Symbol & Exchange: FSE: MOR (Germany) Investor Relations Contact: Dr. Claudia Gutjahr-LOser Investor Relations Contact Phone: [phone] Web: www.morphosys.com Date of Presentation: May 15, 2006 MorphoSys is one of the world's leading biotechnology companies focusing on fully human antibodies. With its proprietary technologies, MorphoSys is developing not only the next generation of therapeutic antibodies, but also antibodies for research and diagnostics purposes. HuCAL(R) (Human Combinatorial Antibody Library) is a very powerful technology for the rapid and automated production of specific antibodies. The most distinctive feature of the library is the capability to optimize fully human antibodies to pre-defined specifications, allowing MorphoSys researchers and their partners to "Engineer the Medicines of Tomorrow". MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in all market sectors. Company: Neurobiological Technologies, Inc. Ticker Symbol & Exchange: NTII NASDAQ Investor Relations Contact: Cheryl Schneider, VP Investor Relations Contact Phone: Porter, LeVay & Rose, Inc. 212-564-4700 Web: www.ntii.com Date of Presentation: Tuesday, May 16, 2006 at 9:45 a.m. Neurobiological Technologies, Inc.is a drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The company's strategy is to in-license and develop early- and later-stage drug candidates that target major medical needs and which can be rapidly commercialized. NTI's experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. We anticipate that we will continue to acquire and develop late-stage neurologic drug candidates and will develop the resources to market these drugs in selected world regions. Our goal is to develop and market drug candidates in the United States, Europe and Asia and we may seek partnerships with pharmaceutical and biotechnology companies to assist us. Company: Neuromed Pharmaceuticals Investor Relations Contact: Bruce Colwill, CFO Investor Relations Contact Phone: [phone] Web: www.neuromed.com Date of Presentation: May 16, 2006 Neuromed is a privately held biopharmaceutical company developing the next generation of chronic pain drugs with pipeline programs in anxiety, epilepsy and cardiovascular disease such as hypertension. Located in Vancouver, Canada and Conshohocken, USA, the Company's drug development programs are designed around validated clinical targets associated with large unmet markets. Neuromed exclusively focuses on calcium channels as drug targets and is the first company to take an orally available drug selectively targeting neuronal calcium channels into human clinical trials. Company: Newron Pharmaceuticals SpA Web: www.newron.com Date of Presentation: 15th May Newron Pharmaceuticals SpA is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule drugs for the treatment of central nervous system (CNS) diseases. Our clinical focus is on neurology and pain.Through continuous research, diligent scientific breakthroughs and ethical use of emerging new technology, Newron Pharmaceuticals aims to provide patients with debilitating CNS disorders effective therapies that significantly improve their quality of life. Newron now has two compounds in clinical trials for three indications: safinamide in Phase III for the treatment of Parkinson's disease and in Phase II for the treatment of Restless Legs Syndrome; and Ralfinamide, a novel compound for the treatment of neuropathic pain in Phase II. Additional projects are in the preclinical phase. Company: Novelos Therapeutics, Inc. Ticker Symbol & Exchange: NVLT OTCBB Investor Relations Contact: Stephen Lichaw Investor Relations Contact Phone: [phone] Web: www.novelos.com Date of Presentation: Monday, May 15, 2006. 9:45am. Novelos Therapeutics, Inc. is a biotechnology company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer, is designed to act as a chemoprotectant and an immunomodulator. NOV-002 is also being developed to treat chemotherapy-resistant ovarian cancer and acute radiation injury. NOV-205, a second compound, is designed to act as a hepatoprotective agent with immunomodulating and antiinflammatory properties. Novelos plans to initiate a U.S.-based NOV-205 clinical trial for chronic hepatitis C by mid-2006. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed. For additional information about Novelos please visit www.novelos. Company: NovaDel Pharma, Inc. Ticker Symbol & Exchange: NVD Investor Relations Contact: MacDougall Biomedical Comm. Investor Relations Contact Phone: Chris Erdman, 508-647-0209 X14 Web: www.novadel.com Date of Presentation: May 16, 2006 NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary lingual spray technology delivery system offers the patient the potential for (i) fast onset of action; (ii) improved drug safety by reducing the required drug dosage and reducing side effects; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies. Company: Oncolytics Biotech Inc. Ticker Symbol & Exchange: ONC:TSX, ONCY:NASDAQ Investor Relations Contact: Cathy Ward Investor Relations Contact Phone: [phone] Web: www.oncolyticsbiotech.com Date of Presentation: Tuesday, May 16 at 11:55 a.m. Oncolytics Biotech Inc. is focused on the development of oncolytic viruses as a novel and effective approach to cancer treatment. Oncolytics' lead product, REOLYSIN(R), is developed from the human reovirus. Oncolytics has completed three human clinical studies with REOLYSIN(R) in Canada and is currently conducting or has permission to conduct another four clinical studies in the U.S. and the U.K. Interim and final results of the first five clinical studies for a variety of advanced cancers have demonstrated evidence of tumour regression with only minor side effects such as mild, flu-like symptoms of short duration. Company: Orexo AB (publ) Ticker Symbol & Exchange: SSE-ORX Investor Relations Contact: Zsolt Lavotha (CEO) Investor Relations Contact Phone: [phone] Web: www.orexo.com Date of Presentation: Monday May 15 Orexo is a pharmaceutical company that focuses on developing new pharmaceutical drugs within areas currently subject to considerable clinical needs. Orexo's products are based on existing pharmaceuticals and the company's patented drug-delivery technologies. Orexo applies its broad expertise in medicine and pharmacy to the further development of existing pharmaceutical substances. By combining well-documented compounds with its own patented drug-delivery methods and its unique expertise in "dry formulations" (for example, tablets), Orexo is able to develop new patented pharmaceuticals. At present, the company has one product on the market, three under clinical development, one of which has been out-licensed in the US, Europe and Japan, two projects in the pharmaceutical formulation phase, and one project in an early development stage. Company: PAION AG Ticker Symbol & Exchange: PA8 FSE Investor Relations Contact: Dr. Peer Nils Schroder Investor Relations Contact Phone: [phone] Web: www.paion.de Date of Presentation: 15.5.2006, 4.55 p.m. PAION, a biopharmaceutical company based in Aachen, Germany, aims to become a leader in developing and commercialising innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need. PAION intends to build an integrated drug portfolio by exploiting its expertise in identifying compounds, licensing or otherwise acquiring them and advancing them through the clinical development and regulatory approval process. PAION's lead product Desmoteplase for the treatment of acute ischaemic stroke is currently in Phase III. Two additional drugs are in clinical development. At the end of 2005, PAION employed 72 people. Company: Panacos Pharmaceuticals Inc. Ticker Symbol & Exchange: PANC (NASDAQ) Investor Relations Contact: Jill Smith Investor Relations Contact Phone: [phone] Web: http://www.panacos.com Date of Presentation: May 16 Panacos is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Panacos' lead candidate, PA-457, is the first in a new class of oral HIV therapeutics under development called maturation inhibitors, discovered by Panacos scientists and their academic collaborators. By targeting a novel step in the virus life cycle, maturation inhibitors are designed to have potent activity against a broad range of HIV, including strains that are resistant to existing classes of drugs. Panacos' proprietary discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Company: Prana Biotechnology Limited Ticker Symbol & Exchange: ASX:PBT / Nasdaq: PRAN Investor Relations Contact: Kathy Price Investor Relations Contact Phone: The Global Consulting Group, 646-284-9430 Web: www.pranabio.com Date of Presentation: May 16, 2006 Prana Biotechnology discoveries, emerging out of MGH at Harvard and the University of Melbourne in Australia, have lead to the development of MPAC's (Metal Protein Attenuating Compounds), which have shown great promise to treat a variety of neurodegenerative disorders. Clinical efficacy (phase 2) was demonstrated in a 'proof of principle' MPAC (PBT1) for Alzheimer's disease. Prana's lead proprietary molecule, PBT2, has successfully completed Phase 1 testing for AD. Furthermore, very encouraging research findings were published demonstrating the efficacy of MPAC's in pre-clinical models of Parkinson's Disease, Huntington's Disease and certain cancers. All of these represent potential therapeutic targets for Prana. Company: Pro-Pharmaceuticals, Inc. Ticker Symbol & Exchange: PRW: Amex Investor Relations Contact: Tony Squeglia Investor Relations Contact Phone: [phone] Web: www.pro-pharmaceuticals.com Date of Presentation: May 15 Pro-Pharmaceuticals is a development stage company engaged in the discovery, development, and commercialization of carbohydrate-based therapeutic compounds. The Company's expertise offers opportunities to provide advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory disease, and viral infections. The Company has initially focused on target delivery of chemotherapy drugs for the treatment of cancer. DAVANAT(R), the Company's lead product candidate, when used with FDA-approved cancer drugs, may increase the efficacy and decrease the toxicity of current chemo treatments. DAVANAT(R) with 5-FU completed a Phase I trial for all solid tumors and is currently in a Phase II colorectal cancer trial. The Company has initiated a Europe-based Phase III colorectal cancer trial and a Phase II trial for bile duct cancer. Company: Proteome Systems Ltd Ticker Symbol & Exchange: PXL/ASX Investor Relations Contact: Lisa Jones Investor Relations Contact Phone: [phone] Web: www.proteomesystems.com Date of Presentation: 15 May 2006 Proteome Systems Limited is an Australian based biotechnology company which discovers and develops diagnostic and therapeutic products. The Company has extensive expertise in the discovery and development of protein biomarkers and their subsequent development for diagnostic use. Our focus is on respiratory disease, neurodegenerative disease, cancer and infectious diseases. The Company's lead diagnostic programmes are Tuberculosis, Prostate Cancer, Ovarian Cancer and Huntington's Disease. Our lead therapeutic programmes are for radiation damage, topical disease and novel antibiotic targets. Company: Provectus Pharmaceuticals Ticker Symbol & Exchange: PVCT.ob Investor Relations Contact: Matt Clawson @ Allen & Caron Investor Relations Contact Phone: [phone] Web: www.pvct.com Date of Presentation: May 16, 2006 Provectus Pharmaceuticals, Inc. is an innovative biopharmaceutical company engaged in the design, development and marketing of pharmaceutical technologies for the treatment of psoriasis, breast cancer, liver cancer and metastatic melanoma. The Company has developed core technologies and intellectual properties surrounding Rose Bengal ("PV-10"), a stable, non-toxic substance that has traditionally been used as an imaging agent in medicine. Provectus is preparing to begin Phase 2 clinical trials for Xantryl(TM), a topical treatment for psoriasis. In oncology, the Company has developed Provecta(TM) for the treatment of metastatic melanoma and recurrent breast cancer. Provecta is currently undergoing Phase 1 clinical trials. Company: Questcor Pharmaceuticals, Inc. Ticker Symbol & Exchange: QSC: AMEX Investor Relations Contact: Eric Liebler, Nisola, LLC [e-mail] Investor Relations Contact Phone: [phone] Web: www.questcor.com Date of Presentation: 05/15/06 Questcor Pharmaceuticals, Inc.(R) (AMEX: QSC) is a specialty pharmaceutical company that develops and commercializes novel therapeutics for the treatment of neurological disorders. Questcor currently markets H.P. Acthar(R) Gel (repository corticotropin injection), an injectable drug indicated for the treatment of exacerbations associated with Multiple Sclerosis and Doral(R) (quazepam) that is indicated for the treatment of insomnia, characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com. Company: Serono International S.A. Ticker Symbol & Exchange: SEO / SRA Investor Relations Contact: Robert Bennett. [phone] Web: www.serono.com Date of Presentation: May 15th, 2006 at 10.30 AM Serono is a global biotechnology leader. The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/ Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R). In addition to being the world leader in reproductive health, Serono has strong market positions in neurology and growth & metabolism and has recently entered the psoriasis area. The Company's research programs are focused on growing these businesses and on establishing new therapeutic areas, including oncology and autoimmune diseases. Currently, there are more than 25 ongoing preclinical and clinical development projects. In 2005, Serono, whose products are sold in over 90 countries, achieved worldwide revenues of US$2,586.4 million. Company: Spectrum Phamaceuticals, Inc. Ticker Symbol & Exchange: SPPI Investor Relations Contact: Jeanie D. Herbert Investor Relations Contact Phone: [phone] Web: www.spectrumpharm.com Date of Presentation: May 16, 9:25 - 9:45 a.m. (EURO) Spectrum Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Irvine, California, engaged in the business of acquiring, developing and commercializing prescription drug products for the treatment of cancer and other unmet medical needs. Spectrum has built a diversified portfolio of proprietary and generic drug products in various stages of development and regulatory approval. For more information, please visit our website at www.spectrumpharm.com. Company: SR Pharma plc. / Atugen AG Ticker Symbol & Exchange: SPA.L (AIM) Investor Relations Contact: Thomas Christely (CEO/Atugen) Investor Relations Contact Phone: [phone] Web: www.srpharma.com & www.atugen.com Date of Presentation: 15 May 2006 SR Pharma plc. is a European biopharmaceutical company based in the UK and Germany and listed on AIM, London. In June 2005 SR Pharma plc has acquired Atugen AG, Berlin, Germany, a leader in RNAi therapeutics. Atugen owns novel, chemically modified proprietary short interfering RNA (siRNA) molecules (AtuRNAi) and a proprietary in vivo delivery system (AtuPLEX) which both have several advantages over conventional siRNA molecules and their delivery. Clinical development of AtuRNAi therapeutic molecules are targeted to start in H1/2007 for systemic applications in advanced cancers. Several AtuRNAi candidates are in pre-clinical development with a corporate partner for other therapeutic indications. Company: Sunesis Pharmaceuticals, Inc. Ticker Symbol & Exchange: SNSS Investor Relations Contact: Eric Bjerkholt Investor Relations Contact Phone: [phone] Web: www.sunesis.com Date of Presentation: May 15, 2006 @ 11:15AM Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. Company: Tactical Therapeutics Inc Investor Relations Contact: Rashida A. Karmali, J.D., Ph.D Investor Relations Contact Phone: [phone] Web: www.tacticaltherapeutics.com Date of Presentation: May 16, 2006 Tactical Therapeutics, Inc. has developed a patented cancer therapeutic that has unique pharmacokinetic properties of faster delivery to target cancer cells and a high clearance rate and reduced toxicity. Specifically, Tactical's drug candidate, CAI Orotate (CAI-O), has overcome all of the disadvantages of a related Merck Inc's discontinued drug- CAI. Tactical has been advised by the FDA to develop CAI-O under the Accelerated Drug Approval Track. The time line is to file the IND in 2007 and the NDA in 2010. Tactical has focused on its drug discovery efforts on therapies that are more effective, less toxic and more cost effective than currently available. Some "targeted" cancer treatments (biologics-AVASTIN) are reducing cancer deaths, but are expensive. Tactical's CAI-O is equally effective in preclinical models but also cost-effective. Company: Threshold Pharmaceuticals, Inc. Ticker Symbol & Exchange: THLD : NASDAQ Investor Relations Contact: Denise Powell Investor Relations Contact Phone: [phone] Web: www.thresholdpharm.com Date of Presentation: May 15, 2006 Threshold is a biotechnology company focused on the discovery, development and commercialization of small molecule therapeutics in middle- and late- stage clinical trials for the potential treatment of benign prostatic hyperplasia (BPH), a disease afflicting tens of millions of men worldwide, and cancer. By selectively targeting tumor or other abnormally-proliferating cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website: http://www.thresholdpharm.com Company: Xenomics, Inc. Ticker Symbol & Exchange: XNOM.OB & XE7 Investor Relations Contact: Dr. L. David Tomei, Ph.D. Investor Relations Contact Phone: [phone] Web: www.xenomics.com Date of Presentation: May 15, 2006 Xenomics is a molecular diagnostic company that has developed a non-invasive, DNA-based urine analysis technology which may be utilized for the detection and monitoring of a wide range of medical subjects including infectious diseases, cancers, prenatal conditions, and others. Xenomics' patented proprietary technology utilizes this fragmented DNA material which has crossed the kidney barrier ("Trans-Renal DNA" or "Tr-DNA") and is available in urine to provide vital information about conditions throughout the body. Xenomics' immediate product focus is in the area of infectious diseases, specifically tuberculosis, and prenatal conditions. The Company plans to launch is first products in these areas in 2007-2008. Company: YM BioSciences Inc. Ticker Symbol & Exchange: TSX: YM; AMEX: YMI; AIM: YMBA Investor Relations Contact Phone: [phone] Web: www.ymbiosciences.com Date of Presentation: May 15/06 YM BioSciences Inc. is a cancer product development company established in Canada in 1994. Its shares are listed on the American Stock Exchange, the London Stock Exchange's AIM and the Toronto Stock Exchange. YM was named one of "Canada's Top 10 Life Sciences Companies" by the Ottawa Life Sciences Council in November 2005. YM BioSciences licenses research products from academic institutions and other biotechnology companies and then focuses on developing these products. Its current clinical development portfolio includes four different anti-cancer products in a number of formulations targeting 10 tumour types as well as novel delivery of opioids for cancer pain. YM BioSciences is advancing drugs through Phase III, II, I/II and also has a number if compounds in pre-clinical development. Company: York Pharma plc Ticker Symbol & Exchange: YRK London Exchange Investor Relations Contact: Rowan Minion, Northbank Commun Investor Relations Contact Phone: [phone] Web: http://www.YorkPharma.com Date of Presentation: 16 May 2006 York Pharma is a speciality pharmaceutical company aimed at discovering, acquiring, developing and commercialising novel and superior prescription dermatological products. The Company's portfolio consists of six first in class products addressing the important anti-fungal, psoriasis, eczema and acne markets that collectively make up 75% of the $10.4bn global prescription dermatology market. Abasol, the Company's lead antifungal product offers features and benefits that York believes will give it a significant competitive advantage in a $2.4bn market. The Company is preparing for its first regulatory approval and commercialisation in Europe in 2006. With Vampex and Sabarep progressing through clinical development for psoriasis and eczema respectively, York is poised to make a significant impact in dermatology. Company: ZIOPHARM Oncology, Inc. Ticker Symbol & Exchange: ZIOP.OB Investor Relations Contact: Suzanne McKenna Investor Relations Contact Phone: [phone] Web: www.ziopharm.com Date of Presentation: Tueday May 16, 2006 ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content, experts, company profiles, survey services and other media services.

Note to Event Organizers: Add your trade show, conference, or event to www.tradeshownews.com, Business Wire's online event calendar. For information, email [e-mail].